NovaBay Pharmaceuticals Provides Update on Phase 2b Data of Auriclosene for Impetigo
06. November 2013 16:15 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 6, 2013 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing non-antibiotic antimicrobial products,...
NovaBay Calls for New Approaches to Antibiotic Drug Development to Slow the Rise of Resistance, Save Lives and Protect the Environment
07. Oktober 2013 07:00 ET
|
NovaBay Pharmaceuticals, Inc.
CDC Study Finds Current Approach is Ineffective and Costs Billions
NovaBay Submits Comments to the FDA Regarding Antibacterial Therapies
EMERYVILLE, Calif., Oct. 7, 2013 (GLOBE NEWSWIRE) -- Dr....
NovaBay CEO Updates Product Pipeline in Video Interview
01. August 2013 08:30 ET
|
NovaBay Pharmaceuticals, Inc.
Data from Three Clinical Studies Expected to be Released in the Next Three to Nine Months
EMERYVILLE, Calif., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Dr. Ron Najafi, Chairman and Chief Executive Officer...
NovaBay Pharmaceuticals Reports Second Quarter 2013 Financial Results and a Clinical/Business Update
01. August 2013 08:15 ET
|
NovaBay Pharmaceuticals, Inc.
Clinical Results From Three Aganocide® Trials to be Reported Over the Next Three to Nine Months
EMERYVILLE, Calif., Aug. 1, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE:NBY),...
NovaBay Pharmaceuticals to Present at Southern California Investor Conference
31. Juli 2013 16:05 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., July 31, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biotechnology company focused on the topical, anti-infective market, today...
NovaBay Pharmaceuticals to Present at JMP Securities 8th Annual Healthcare Conference
02. Juli 2013 08:30 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., July 2, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biotechnology company focused on the topical, anti-infective market, today announced...
NovaBay Executive Interviewed on CEOLIVE TV
01. Juli 2013 09:55 ET
|
NovaBay Pharmaceuticals, Inc.
Highlights New Approach to Address Global Antibiotic Resistance Crisis
EMERYVILLE, Calif., July 1, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE:NBY), an advanced clinical-stage...
NovaBay Supports Legislation to Attack Antibiotic Resistance
17. Juni 2013 08:50 ET
|
NovaBay Pharmaceuticals, Inc.
CEO Cites Growing Crisis
EMERYVILLE, Calif., June 17, 2013 (GLOBE NEWSWIRE) -- Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) today announced...
NovaBay Pharmaceuticals Mid-Year Clinical Update
11. Juni 2013 08:00 ET
|
NovaBay Pharmaceuticals, Inc.
Clinical Results From Three Auriclosene Phase 2 Trials Expected in Second Half of This Year
EMERYVILLE, Calif., June 11, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc., (NYSE:NBY), a...
NovaBay Pharmaceuticals and Virbac Enter Into a Collaboration and License Agreement for Animal Health
28. Mai 2013 03:05 ET
|
NovaBay Pharmaceuticals, Inc.
Virbac Exercises Option to Develop Auriclosene for Use in Global Veterinary Markets
EMERYVILLE, Calif. and CARROS, France, May 28, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc.,...